12th October 2022
EIT Health-supported NALA.care has closed a partnership with cosmetics and beauty leader, La Roche-Posay Switzerland. This is an enormous step for the company on its way to enabling eczema patients to live healthier and happier lives.
NALA.care offers a ‘fast-track to happy skin’ by cutting down the time it takes from being diagnosed to achieving healthy skin. The company does this by digitising the current eczema therapy guideline, adding science-based holistic elements, and boosting it with data and Artificial Intelligence (AI).
The Swiss company aims to replace lengthy doctor’s appointments by sending the patient expert knowledge on the topic. Their app identifies each patient´s eczema trigger factors and skin-supporting factors that may help to counter these triggers.
“The challenge today is that patients get treated with a one-size-fits-all approach. This forces them to customise their own treatment plan by doing a year/decade-long journey of ‘expert hopping’ (i.e., dermatologists, allergists, GP, nutritionists, psychologists etc.) and ‘trial and error’ to find out the medication and cremes that help and the allergens, nutrition and behaviour that trigger flare-ups. We want to change this since we know the challenges of being patients ourselves. We use AI to cut the time between diagnosis and a happy skin (therapy success) from many years/decades to just a couple of weeks,” says Jeremy Henrichs, CEO and co-founder of NALA.care.
La Roche-Posay Switzerland is going to promote the NALA app through its broad network of key opinion leaders, doctors, and customers in Switzerland. NALA will also be implementing additional product information for relevant eczema products on the app, including the possibility to order their favourite products or a free trial package, directly.
EIT Health has supported the start-up through the Wild Card programme in 2020, which enabled the company to experience world-class training and mentoring.
How can young scientists move to innovation roles?
Q&A with Carmen Schweicker
EIT Health named top business accelerator by UBI Global
Learn more about the achievement
Arthex Biotech closes a €42M Series B financing round
Find out more about our support